Clinical Trial Update: Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating losartan to mitigate knee arthrofibrosis after total knee arthroplasty has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Arthrofibrosis

Drugs mentioned

• Losartan (losartan)

Snippet

Sponsor: NYU Langone Health | Conditions: Arthrofibrosis of Knee | Phase 4 | Status: WITHDRAWN